Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Jazz Pharmaceuticals plc
Report date December 02, 2025 · Filed December 04, 2025
Section 16 reporting ended · disclosed 2025-12-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 25,811 |
Reported balance
After 2025-12-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-02 · Tax withholding · Disposed 603 · Balance 25,811 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2: Reflects the cancellation for no value of 2,258 RSU shares on December 1, 2025. |
| Ordinary SharesSEC Table I · non-derivative | Indirectby Trust | 4,445 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,445 F3: Shares are held for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
F2: Reflects the cancellation for no value of 2,258 RSU shares on December 1, 2025.
F3: Shares are held for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 02, 2025 Filed Dec 4, 2025 22:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 603 | $173.07 | $104,361.21 |
DisclosureSEC source: 0001397661-25-000009 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,811 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Reflects the cancellation for no value of 2,258 RSU shares on December 1, 2025. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 21:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,805 | $111.25 | $200,806.61 |
DisclosureSEC source: 0001765581-25-000096 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,672 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000096 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,477 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document |
| August 06, 2024 Filed Aug 6, 2024 22:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,484 | $111.35 | $165,243.40 |
DisclosureSEC source: 0001765581-24-000075 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,970 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 22:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000075 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,454 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,241 | $138.16 | $171,454.70 |
DisclosureSEC source: 0001765581-23-000096 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,723 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $137.78 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000096 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,964 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $81.76 | $0.00 |
DisclosureSEC source: 0001765581-23-000034 · edgardoc.xml · derivative · entry 4 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,500 shares Expires 2013-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Option Plan. This option vested in 12 equal monthly installments beginning on September 1, 2013. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,690 | $138.39 | $372,267.49 |
DisclosureSEC source: 0001765581-23-000034 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,889 F1 · kind: Shares sold to pay option price from the exercise of stock options. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 23:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,500 | $81.76 | $367,920.00 |
DisclosureSEC source: 0001765581-23-000034 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,089 | $152.33 | $165,883.45 |
DisclosureSEC source: 0001765581-22-000092 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,079 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:34 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000092 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,168 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 21:37 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,306 | $147.96 | $193,235.76 |
DisclosureSEC source: 0001765581-21-000106 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,607 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| July 29, 2021 Filed Aug 2, 2021 22:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-21-000077 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,913 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 4,513 | $156.44 | $706,003.34 |
DisclosureSEC source: 0001765581-20-000111 · edgardoc.xml · nonDerivative · entry 4 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,667 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $156.00 to $156.99 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,746 | $155.14 | $270,867.28 |
DisclosureSEC source: 0001765581-20-000111 · edgardoc.xml · nonDerivative · entry 3 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,180 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $154.91 to $155.73 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,740 | $153.74 | $421,255.27 |
DisclosureSEC source: 0001765581-20-000111 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,926 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.355 to $154.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 21:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 2,001 | $152.57 | $305,294.77 |
DisclosureSEC source: 0001765581-20-000111 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,666 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.319 to $152.83 The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionPhantom Stock · Derivative | 22,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001765581-20-000105 · edgardoc.xml · derivative · entry 3 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 22,249 shares Expires 2020-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On November 2, 2020, the Reporting Person's 22,249 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares. F1 · price: On November 2, 2020, the Reporting Person's 22,249 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares. Read SEC document |
| November 02, 2020 Filed Nov 5, 2020 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 22,249 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001765581-20-000105 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On November 2, 2020, the Reporting Person's 22,249 phantom stock rights under the Issuer's Amended and Restated Directors Deferred Compensation Plan were settled for an equal number of the Issuer's ordinary shares. Read SEC document |
| August 07, 2020 Filed Aug 10, 2020 20:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 931 | $125.87 | $117,185.71 |
DisclosureSEC source: 0001765581-20-000077 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,418 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 6,765 | $0.00 Strike: $127.07 | $0.00 |
DisclosureSEC source: 0001765581-20-000077 · edgardoc.xml · derivative · entry 4 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Underlying: Ordinary Shares · 6,765 shares Expires 2030-08-05 F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in full on July 30, 2021. Read SEC document |
| August 06, 2020 Filed Aug 10, 2020 20:48 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-20-000077 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,349 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 30, 2021. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,750 | $147.82 | $997,774.20 |
DisclosureSEC source: 0001765581-19-000098 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 4,445 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.77 to $148.05. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Shares are held for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 726 | $135.65 | $98,481.68 |
DisclosureSEC source: 0001765581-19-000070 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,644 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $135.60 to $135.65. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,805 | $0.00 Strike: $137.12 | $0.00 |
DisclosureSEC source: 0001765581-19-000070 · edgardoc.xml · derivative · entry 4 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,805 Underlying: Ordinary Shares · 4,805 shares Expires 2029-08-07 F5 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. F5 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 21:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000070 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,370 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 1, 2020. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 22:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 660 | $176.61 | $116,563.00 |
DisclosureSEC source: 0001232524-18-000148 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,450 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $176.9814. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,735 | $0.00 Strike: $177.73 | $0.00 |
DisclosureSEC source: 0001232524-18-000148 · edgardoc.xml · derivative · entry 4 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,735 Underlying: Ordinary Shares · 3,735 shares Expires 2028-08-08 F5 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. F5 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2018. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 22:42 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,495 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000148 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,110 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 2, 2019. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3 | $144.11 | $432.34 |
DisclosureSEC source: 0001232524-17-000146 · edgardoc.xml · nonDerivative · entry 3 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,810 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 11, 2017 Filed Aug 14, 2017 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 659 | $142.36 | $93,815.24 |
DisclosureSEC source: 0001232524-17-000146 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,813 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,415 | $0.00 Strike: $143.66 | $0.00 |
DisclosureSEC source: 0001232524-17-000146 · edgardoc.xml · derivative · entry 5 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,415 Underlying: Ordinary Shares · 3,415 shares Expires 2027-08-09 F4 · kind: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 21:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000146 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,472 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. F1 · shares: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018. Read SEC document |
| November 14, 2016 Filed Nov 15, 2016 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 500 | $112.45 | $56,223.50 |
DisclosureSEC source: 0001232524-16-000386 · edgardoc.xml · nonDerivative · entry 3 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 2,000 F2 · price: Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $112.4000 to $112.4588. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were made. F1 · ownership.nature: Shares were acquired for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 300 | $114.33 | $34,299.00 |
DisclosureSEC source: 0001232524-16-000386 · edgardoc.xml · nonDerivative · entry 2 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,500 F1 · ownership.nature: Shares were acquired for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 22:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | PurchaseOrdinary Shares | 1,200 | $114.30 | $137,165.64 |
DisclosureSEC source: 0001232524-16-000386 · edgardoc.xml · nonDerivative · entry 1 O'Keefe Kenneth W · CIK 0001397661 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,200 F1 · ownership.nature: Shares were acquired for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.